LTR 146: Ganesh Sabat on Scaling MedTech Through Quality

Summary“A company can become world class the day the quality team decides.”In this Let’s Talk Risk! conversation, host Naveen Agarwal engages with Ganesh Sabat, former former CEO of Sahajanand Medical Technologies (SMT) and now Founder & Managing Partner of MedArtha Capital about a simple but hard truth: global scale in MedTech is earned through quality execution, not marketing narratives.Ganesh walks through SMT’s transformation from an innovative startup into a globally recognized cardiovascular device company, then zooms out to India’s broader MedTech ambition. We unpack what’s missing (talent depth, shared learning, true design ownership), what’s emerging (incubation + device parks + incentives), and why quality leaders are the real “make-or-break” force behind India’s credibility on the world stage.Listen to the full 30-minute podcast or jump to a section of interest listed below. Chapters00:00 Welcome and Introduction02:09 SMT story: from “innovative startup” to global scale04:54 The turning point: why Ganesh bet on quality as the growth lever06:13 What investors demanded: proof, discipline, and scalable systems08:39 India ecosystem reality: pharma-quality mindset vs device-grade rigor11:22 “Quality as a system”: building defect prevention into process + design15:21 Building the ecosystem: why shared learning + capability depth matter18:58 Challenges and opportunities for MedTech startup21:02 Achieving global success not through low-cost but high quality24:25 Closing remarksIf you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.Suggested links:LTR: What QA/RA Professionals Need to Know About MedTech in India.LTR: Navigating the Regulatory Landscape for SaMD in India.LTR: Atty Chakraborty on India’s Rising MedTech Sector.Key Takeaways* Quality isn’t a checkpoint at the end. It’s a design-and-system discipline built upstream.* SMT’s scaling story is framed as “investing in quality,” then validating it through clinical proof and execution rigor.* Customer trust and investor confidence converge on the same requirement: consistent, reliable quality (and safety) at global standards.* India’s MedTech ecosystem is growing rapidly, but limited depth of specialized quality talent slows the curve.* Moving from pharma-style quality to device-grade quality requires engineering capability, process ownership, and design mastery.* Many early-stage companies need more than capital. They need experienced, operator-led “corridor finding” through regulatory + commercialization complexity.* Device parks and incentives can accelerate manufacturing and scale, but credibility still hinges on execution discipline.* Ganesh’s closing challenge is direct: quality teams hold the leverage to make companies—and countries—world class.KeywordsQuality culture; design controls; engineering-led quality; global scale-up; cardiovascular devices; stents; clinical evidence; India MedTech; regulatory rigor; manufacturing excellence.About Ganesh SabatGanesh Sabat is is the Founder & Managing Partner of MedArtha Capital, an visionary investment platform backing MedTech, medical device, and digital healthcare companies emerging from India and scaling globally.Previously, Ganesh spent ~15+ years as a senior executive, most recently as CEO of Sahajanand Medical Technologies (SMT), where he helped scale a highly regulated cardiovascular medical device business across innovation, manufacturing, quality, regulatory pathways, and international markets, building presence across 80+ countries and driving sustained growth.Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.DisclaimerInformation and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe